The following is a list of current portfolio companies and some companies we have exited:
- Advanced Bionics Corporation
- Agile RF, Inc.
- Alsius Corporation
- Centaur Pharmaceuticals/Renovis
- ClarVista Medical Inc.
- Clean Diesel Technologies, Catalytic Solutions, Inc.
- FzioMed Inc.
- Genocea Biosciences
- GRT, Inc.
- Imaginab, Inc.
- INTARCIA THERAPEUTICS, INC.
- OvaScience, Inc.
- Sofie Biosciences, Inc.
- Solaria Corp.
- The NanoSteel Company
- Tilford Pinson Exploration, LLC
- Universal Space Network
- Urban Electric Power, Inc.
- Visterra, Inc.
- ZioPharm Oncology, Inc.
- ZT3 Technologies Inc.
Advanced Bionics Corporation
Advanced Bionics® is dedicated to the development of neurostimulation products: implantable devices that generate sophisticated electrical pulses directed to nerves and muscles for the treatment of disabling conditions. Advanced Bionics technologies include treatments for deafness and chronic pain. The company is also developing other sophisticated neurostimulation devices to address additional challenges in many fields including blindness, tremor and spasticity, urinary incontinence, and functional restoration of paralyzed limbs. Advanced Bionics has been acquired by Boston Scientific Corporation.
Agile RF, Inc.
Agile RF uses a novel material technology to design and fabricate tunable integrated components that have a wide range of applications in wireless communications. The key feature of Agile’s components and circuits is tunability; making their products much more than simply integrated passive circuits. Agile’s expertise in materials science and RF circuit design has enabled them to exploit the properties of newly developed thin film materials in innovative RF designs. Agile has exclusively licensed certain of its key technologies to TriQuint (Nasdaq:TNQT).
Alsius Corporation (Nasdaq CM: ALUS)
ALSIUS (Latin translation for “Cool”) is the worldwide leader in advanced patient temperature management therapies. Alsius Intravascular Temperature Management™ gives health care providers the power and control they need to rapidly, safely, and effectively manage the core body temperature of critically ill or surgical patients. Alsius has been acquired by a wholly-owned subsidiary of ZOLL Medical Corporation. (Nasdaq:ZOLL).
Centaur Pharmaceuticals Corporation/Renovis (Nasdaq GM: RNVS)
Centaur Pharmaceuticals developed a novel class of small molecule pharmaceutical compounds for the treatment of neurodegenerative and inflammatory diseases such as acute stroke, dementia, rheumatoid arthritis, myocardial ischemia and Parkinson’s disease. Renovis is a biopharmaceutical company with a primary focus on the discovery, development and commercialization of drugs to treat neurological diseases and disorders. Renovis acquired Centaur Pharmaceuticals, Inc. in December 2002.
ClarVista Medical Inc.
ClarVista has developed the Harmoni modular intra-ocular lens system. The two piece Harmoni IOL system enables vision optimization through better initial positioning of the lens, and the safe and easy exchange of the lens optic when required. Initial studies also indicate that the risk of development of secondary cataracts is significantly reduced by the Harmoni system.
Clean Diesel Technologies (NASDQ CM: CDTI) / Catalytic Solutions, Inc.
Clean Diesel Technologies (CDTI) and Catalytic Solutions, Inc. (CSI) is a vertically integrated global manufacturer and distributor of emissions control systems and products, focused in the heavy duty diesel (HDD) and light duty vehicle (LDV) markets. CSI invented Mixed Phase Catalyst (MPC®) technology, a fundamentally unique and patented materials technology for the development of catalysts for emissions control (environment) and chemical processes. CDTI and CSI merged in December 2010.
FzioMed is engaged in the development and commercialization of advanced, absorbable biosurgery products. FzioMed’s product platform is an innovative polymer technology called Oxiplex®. The properties of Oxiplex make it an ideal and versatile biosurgery material. A key focus for use of Oxiplex® is the prevention of post-surgical adhesions. Adhesions are abnormal fibrous bands of scar tissue that form attachments to normally independent organs and tissues. Adhesions create complications which may require further surgical intervention.
Genocea Biosciences (Nasdaq:GNCA)
Genocea Biosciences has unique platform technology which rapidly identifies antigens that stimulate protective T-cell responses that are critical to generating protective and long-term immunity against a wide array of diseases. Its platform has potential to revolutionize vaccines and immunotherapies for a range of infectious diseases, cancers and autoimmune diseases. Current vaccine development programs include Herpes Simplex Virus-2 (HSV-2), Pneumococcus, Chlamydia, HSV-2 prophylaxis, and Malaria.
GRT, Inc. has developed proprietary process chemistry that converts methane to gasoline or other hydrocarbon fuels and chemicals. The GRT process is highly flexible and can be applied to make a wide variety of high volume chemicals and liquid fuels including olefins, aromatics, and high octane gasoline blend stocks. Unlike current technologies (Fischer-Tropsch chemistry and thermal cracking), GRT’s technology does not require high temperatures or pressures to create the gas to liquids reactions, thus providing significant savings in capital costs and operating expenses. GRT has licensed certain of its key technologies to Marathon Oil Corporation (NYSE:MRO).
ImaginAb facilitates the promise of personalized medicine through creation of companion diagnostics for patient stratification and targeted molecular therapy. ImaginAb’s technology enables antibodies to be re-engineered into smaller proteins (fragments) with rapid kinetics suitable for diagnostic imaging, while maintaining target biospecificity. In this way true companion in vivo diagnostics can be developed that enable target expression to be profiled in tissues in a non-invasive, whole-body manner.
INTARCIA THERAPEUTICS, INC.
Intarcia is committed to developing innovative therapies utilizing its Medici Drug Delivery System™ that have the potential to transform the prevention and management of serious chronic diseases by optimizing the efficacy, continuous administration and tolerability of drug therapies. Intarcia's novel technology, the Medici Drug Delivery System™, is a proprietary subcutaneous delivery system comprised of (i) a technology that stabilizes proteins, peptides, antibody fragments, and other highly potent small molecules at or above human body temperatures for up to three years or more; (ii) a matchstick-sized osmotic mini-pump that is placed just under the skin to deliver a continuous and consistent flow of medication; and (iii) placement technology including proprietary tools designed to provide an optimal user experience.Intarcia is currently using the Medici Drug Delivery System™ to target Type 2 Diabetes with their lead product candidate ITCA 650.
Lixivia applies proprietary processes and bio-derived/inspired chemicals to dramatically improve the recovery of precipitated calcium carbonates, calcium salts and rare earth metals from industrial mineral waste products.
OvaScience, Inc. (Nasdaq: OVAS)
OvaScience is focused on the discovery, development and commercialization of new treatments for female infertility. Utilizing patented technology, OvaScience is translating innovative research in egg precursor germline stem cells to make in vitro fertilization (IVF) more effective and safer.
Sirtris Pharmaceuticals (Nasdaq GM: SIRT)
Sirtris Pharmaceuticals is a biopharmaceutical company discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Its drug candidates are designed to mimic the beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of an enzyme called SIRT1, a member of a recently discovered class of enzymes called sirtuins. Sirtris has been acquired by GlaxoSmithKline.
Sofie Biosciences Inc.
Sofie is transforming molecular medicine by expanding the practical and cost effective use of PET (positron emission tomography). By creating world class “bench-top” scanners and the first ever automated in-lab radiochemistry synthesis of probes, Sofie has severed the leash to a centralized PET “core”. This giant step forward enables cost effective preclinical use of PET. Sofie is also developing a proprietary family of new radiopharmaceuticals and PET biomarkers that image the activation of the immune system; which in turn will enable the diagnosis and treatment of complex diseases.
Solaria Corp. manufactures low-concentration photovoltaic modules designed for ground-mounted tracking systems. Solaria’s proprietary manufacturing processes require only a fraction of the capital per watt of manufacturing capacity needed by standard industry processes. Based on its patented technology, Solaria’s modules provide reliable performance while matching form, fit and performance of conventional PV modules.
The NanoSteel Company
NanoSteel combines the compelling attributes of iron-based alloys with new chemistries and mechanisms to deliver material properties and performance characteristics outside the boundaries of existing steels. NanoSteel has created progressive generations of iron-based alloys from metallic coatings to foils to powder metals and sheet steel. Current focus areas are strong and formable sheet steels (a combination of high strength and high ductility in cold formable steel) for automotive lightweighting applications and hard metal powders for 3D printing.
Tilford Pinson Exploration, LLC/Pittsburg Gathering
Tilford Pinson Exploration, LLC (TPX) is an oil and gas exploration and development company focused in the Arkoma Basin of southeastern Oklahoma. TPX’s business strategies include development of coal-bed methane gas reserves utilizing horizontal drilling technology, and the use of 3-D seismic imaging to explore for hydrocarbon reserves in mature, complexly structured areas. TPX employs state-of-the-art technology to maximize production in the short term while creating long term value via future drilling opportunities. Pittsburg Gathering LLC designs, builds, and operates natural gas gathering systems. Pittsburg Gathering LLC collects natural gas at the wellhead from TPX and third party operators, then compresses, transports and treats the gas as required prior to resale to interstate and intrastate markets.
Urban Electric Power, Inc.
Urban Electric Power (UEP) is commercializing proprietary zinc anode rechargeable battery technology for applications ranging from car batteries, to power protection to grid-scale storage. UEP technology uses non-toxic, 100% recyclable materials without lead, heavy metals, or flammable electrolytes. UEP offers substantial cost benefits compared to existing battery chemistries because of the extended cycle life, high capacity at high charge/discharge rates, and low cost of starting materials.
Universal Space Network
Founded by aerospace pioneer Charles “Pete” Conrad, Jr., Universal Space Network, Inc. (USN) is a leader in space operations for telemetry, tracking and control (TT&C) services. Offering responsive, reliable and cost-effective solutions to the global government and commercial space community, USN provides unparalleled coverage through a seamless network of worldwide satellite tracking and communications assets. USN has been acquired by The Swedish Space Corporation.
Visterra uses its proprietary computational technology to generates unique information that guides the discovery and development of novel antibodies for the treatment and prevention of major diseases. The company’s lead product candidates are a broad spectrum human monoclonal antibody for the prevention and treatment of both seasonal and pandemic influenza, and an antibody to treat all four strains of dengue virus.
Ziopharm Oncology, Inc. (Nasdaq: ZIOP)
ZIOPHARM is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.
ZT3 Technologies, Inc.
ZT3 is developing next generation thermoelectric devices for the conversion of waste heat to electricity, and solid state cooling and heating. Using advanced materials engineering and proprietary manufacturing processes ZT3 seeks to dramatically increase the efficiency and reduce the cost of thermoelectric devices. Simply through the harvest of heat energy that is otherwise lost, thermoelectric devices can create electricity without additional environmental impact (no emissions of any pollutants or greenhouse gases).